Search research articles
Contact Us
Filters
Showing results (1081-1090 of 1,129) with videos related to
Page
of 113
Sort By:
The Journal of Clinical Investigation
|
October 1, 2019
DNA priming and gp120 boosting induces HIV-specific antibodies in a randomized clinical trial
Nadine G Rouphael, Cecilia Morgan, Shuying S Li, et al.
Plos One
|
January 30, 2010
Phase 1 safety and immunogenicity evaluation of ADVAX, a multigenic, DNA-based clade C/B' HIV-1 candidate vaccine
Sandhya Vasan, Sarah J Schlesinger, Yaoxing Huang, et al.
Clinical and Vaccine Immunology : CVI
|
September 26, 2014
Phase I/II randomized trial of safety and immunogenicity of LIPO-5 alone, ALVAC-HIV (vCP1452) alone, and ALVAC-HIV (vCP1452) prime/LIPO-5 boost in healthy, HIV-1-uninfected adult participants
Sharon E Frey, Laurence Peiperl, M Juliana McElrath, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
June 4, 2019
The Emperor's New Clothes: PRospective Observational Evaluation of the Association Between Initial VancomycIn Exposure and Failure Rates Among ADult HospitalizEd Patients With Methicillin-resistant Staphylococcus aureus Bloodstream Infections (PROVIDE)
Thomas P Lodise, Susan L Rosenkranz, Matthew Finnemeyer, et al.
The Journal of Infectious Diseases
|
January 10, 2014
Specificity and 6-month durability of immune responses induced by DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particles
Paul A Goepfert, Marnie L Elizaga, Kelly Seaton, et al.
Journal of Virology
|
August 23, 2019
Fc Gamma Receptor Polymorphisms Modulated the Vaccine Effect on HIV-1 Risk in the HVTN 505 HIV Vaccine Trial
Shuying S Li, Peter B Gilbert, Lindsay N Carpp, et al.
Blood Advances
|
December 9, 2024
The roadmap to integrate diversity, equity, and inclusion in hematology clinical trials: an American Society of Hematology initiative
Alice Kuaban, Alysha K Croker, Jeffrey Keefer, et al.
Plos One
|
September 3, 2015
Effect of rAd5-Vector HIV-1 Preventive Vaccines on HIV-1 Acquisition: A Participant-Level Meta-Analysis of Randomized Trials
Yunda Huang, Dean Follmann, Martha Nason, et al.
Journal of AIDS & Clinical Research
|
November 21, 2015
Safety and Immunogenicity of a Recombinant Adenovirus Serotype 35-Vectored HIV-1 Vaccine in Adenovirus Serotype 5 Seronegative and Seropositive Individuals
Jonathan D Fuchs, Pierre-Alexandre Bart, Nicole Frahm, et al.
The Journal of Infectious Diseases
|
May 21, 1998
Immune responses to human immunodeficiency virus (HIV) type 1 induced by canarypox expressing HIV-1MN gp120, HIV-1SF2 recombinant gp120, or both vaccines in seronegative adults. NIAID AIDS Vaccine Evaluation Group
M L Clements-Mann, K Weinhold, T J Matthews, et al.
Page
of 113
Search research articles
Search
Showing results (1081-1090 of 1,129) with videos related to
Sort By:
Page
of 113
The Journal of Clinical Investigation
|
October 1, 2019
DNA priming and gp120 boosting induces HIV-specific antibodies in a randomized clinical trial
Nadine G Rouphael, Cecilia Morgan, Shuying S Li, et al.
Plos One
|
January 30, 2010
Phase 1 safety and immunogenicity evaluation of ADVAX, a multigenic, DNA-based clade C/B' HIV-1 candidate vaccine
Sandhya Vasan, Sarah J Schlesinger, Yaoxing Huang, et al.
Clinical and Vaccine Immunology : CVI
|
September 26, 2014
Phase I/II randomized trial of safety and immunogenicity of LIPO-5 alone, ALVAC-HIV (vCP1452) alone, and ALVAC-HIV (vCP1452) prime/LIPO-5 boost in healthy, HIV-1-uninfected adult participants
Sharon E Frey, Laurence Peiperl, M Juliana McElrath, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
June 4, 2019
The Emperor's New Clothes: PRospective Observational Evaluation of the Association Between Initial VancomycIn Exposure and Failure Rates Among ADult HospitalizEd Patients With Methicillin-resistant Staphylococcus aureus Bloodstream Infections (PROVIDE)
Thomas P Lodise, Susan L Rosenkranz, Matthew Finnemeyer, et al.
The Journal of Infectious Diseases
|
January 10, 2014
Specificity and 6-month durability of immune responses induced by DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particles
Paul A Goepfert, Marnie L Elizaga, Kelly Seaton, et al.
Journal of Virology
|
August 23, 2019
Fc Gamma Receptor Polymorphisms Modulated the Vaccine Effect on HIV-1 Risk in the HVTN 505 HIV Vaccine Trial
Shuying S Li, Peter B Gilbert, Lindsay N Carpp, et al.
Blood Advances
|
December 9, 2024
The roadmap to integrate diversity, equity, and inclusion in hematology clinical trials: an American Society of Hematology initiative
Alice Kuaban, Alysha K Croker, Jeffrey Keefer, et al.
Plos One
|
September 3, 2015
Effect of rAd5-Vector HIV-1 Preventive Vaccines on HIV-1 Acquisition: A Participant-Level Meta-Analysis of Randomized Trials
Yunda Huang, Dean Follmann, Martha Nason, et al.
Journal of AIDS & Clinical Research
|
November 21, 2015
Safety and Immunogenicity of a Recombinant Adenovirus Serotype 35-Vectored HIV-1 Vaccine in Adenovirus Serotype 5 Seronegative and Seropositive Individuals
Jonathan D Fuchs, Pierre-Alexandre Bart, Nicole Frahm, et al.
The Journal of Infectious Diseases
|
May 21, 1998
Immune responses to human immunodeficiency virus (HIV) type 1 induced by canarypox expressing HIV-1MN gp120, HIV-1SF2 recombinant gp120, or both vaccines in seronegative adults. NIAID AIDS Vaccine Evaluation Group
M L Clements-Mann, K Weinhold, T J Matthews, et al.
Page
of 113